---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-020809"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:31:24.760715+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte appoints independent director John Peter Gutfreund; he and fund invest $10.5M

## Summary
- John Peter Gutfreund elected independent director effective July 28, 2022; to chair Finance Committee.
- Gutfreund invested $1M in Series A Preferred Stock (1,176.48 shares) in April 2022 registered direct offering.
- Halle Special Situations Fund LLC, affiliated with Gutfreund, purchased ~$9.5M in common stock and warrants in April 2022.
- CEO expects to bring three major products through reimbursement and to market over next four quarters.

## SEC filing metadata
- accession: 0001493152-22-020809
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/0001493152-22-020809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-020809
- JSON: https://secwatch.observer/filing/0001493152-22-020809.json
- Plain text: https://secwatch.observer/filing/0001493152-22-020809.txt

## Key facts
- Executive change
  John Peter Gutfreund was elected as Director at Insight Molecular Diagnostics Inc..
  - Action: elected
  - Role: Director
  source text: Effective July 28, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (“Oncocyte” or the “Company”) elected John Peter Gutfreund, age 36, to serve as a director on the Board, with a term that expires at the Annual Meeting of Shareholders of the Company to be held in 2023 or until his earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/0001493152-22-020809-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.